Taiwan Advance Bio-Pharmaceutical Inc

Capital Structure and Liquidity Taiwan Advance Bio-Pharmaceutical Inc has a debt-to-equity ratio of 0.87, indicating a relatively balanced capital structure. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. With cash and equivalents of TWD 140.7 million and long-term debt of TWD 248.6 million, the firm's liquidity risk is assessed as medium. ### Profitability and Returns The company's profitability metrics are not explicitly provided in the valuation snapshot, but its operating cash flow of TWD 53.1 million suggests some level of operational efficiency. Given the industry's focus on high-margin biotechnology services, the firm's performance should be benchmarked against the cohort median for Biotechnology & Medical Research in terms of return on invested capital (ROIC) and operating margins. ### Segments and Geographic Exposure The company operates in multiple biotechnology service segments, including veterinary drug residue detection, stem cell preservation, and genetic testing. Its geographic exposure is primarily in Taiwan, with additional operations in Asia, the Americas, and Europe. Revenue concentration data is not provided, but the firm's international presence suggests a moderate level of diversification. ### Growth Trajectory The company's growth trajectory is not quantified in the outlook, but its current revenue of TWD 364.8 million provides a baseline for future performance. The firm's expansion into international markets and its involvement in high-growth biotechnology services may support revenue growth in the coming years. ### Risk Factors The company faces medium liquidity risk due to its negative net cash position after debt. Dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. The firm's capital expenditures of TWD -33.4 million suggest a focus on cost control rather than aggressive expansion. ### Recent Events No specific recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic direction or operational changes.